Abstract 931P
Background
Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) ineligible for curative local therapy typically receive first-line (1L) systemic treatment with platinum-based chemotherapy and pembrolizumab or cetuximab. However, early recurrent patients (<6 months from the last curative local treatment) have been excluded from most 1L systemic treatment studies. Therefore, treatment outcomes for early recurrent patients, the impact of different time-to-recurrence intervals (TTRI), and the influence of recurrence patterns on survival remain unclear.
Methods
We analyzed non-curable R/M-HNSCC patients at our institution between 1/2008 and 6/2020. The study aimed to evaluate outcomes of early recurrent patients receiving 1L systemic treatment and assess TTRIs and recurrent patterns' impact on survival.
Results
234 of 1,281 eligible patients were included. Platinum-based doublet chemotherapy was the predominant 1L treatment. Significant differences in PFS and OS were observed among TTRI groups. In early recurrent patients, those receiving platinum-based doublet and monotherapy showed significantly longer OS compared to best supportive care (BSC). Locoregional recurrence was the most common pattern (47%), followed by distant metastasis (22%) and both (20%). Different R/M-HNSCC patterns were significantly associated with OS (p=0.019), but not PFS (p=0.790). In multivariate analysis, TTRI of ≥12 months correlated with PFS (HR 0.51; p=0.004) and OS (HR 0.58; p=0.009), while recurrence pattern did not. Table: 931P
TTRI | <6 month (47%) | 6-12 month (22%) | >12 month (20%) | De novo M1 (11%) | p-value |
All PFS (months) | 2.9 | 2.8 | 5.0 | 3.8 | 0.028 |
All OS (months) | 4.1 | 5.1 | 8.8 | 5.3 | 0.006 |
OS of patients with 1L treatment Platinum-doublet Monotherapy BSC | 5.8 4.1 2.5 | 8.4 12.7 2.3 | <0.001 |
Conclusions
In our study, R/M-HNSCC patient survival was significantly influenced by TTRI, while recurrence pattern was not. Despite poor prognosis, early recurrent patients benefited from systemic treatments. TTRI should be a stratification factor in future clinical trials, as varying prognoses were observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Ngamphaiboon: Financial Interests, Personal, Invited Speaker: Roche, MSD, Merck, Eisai; Financial Interests, Personal, Advisory Board: BeiGene, BMS, Roche, MSD, Eisai, Merck; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Principal Investigator: RAPT therapeutics, Boehringer Ingelheim Pharmaceuticals, MSD, Roche, BeiGene, Pfizer; Financial Interests, Institutional, Project Lead: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12